Skip to main content

Table 1 Summary of participant characteristics

From: A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)

 All participants (n = 15)Serelaxin (n = 11)Placebo (n = 4)
Age (years)56 (43–69)56 (43–69)59 (54–63)
Gender (% male)11 (73%)8 (73%)3 (75%)
Ethnicity (% Caucasian)15 (100%)11 (100%)4 (100%)
Aetiology of cirrhosis
 Alcohol alone10 (67%)8 (73%)2 (50%)
 NAFLD2 (13%)1 (9%)1 (25%)
 HCV alone1 (7%)1 (9%)0
 HCV + HBV1 (7%)01 (25%)
 Cryptogenic1 (7%)1 (9%)0
 Child–Pugh class A9 (60%)6 (54%)3 (75%)
 Child–Pugh class B6 (40%)5 (45%)1 (25%)
 Child–Pugh class C000
Current/previous liver-related complications
 Ascites8 (53%)6 (55%)2 (50%)
 Spontaneous bacterial peritonitis000
 Hepatic encephalopathy4 (27%)3 (27%)1 (25%)
 Variceal bleeding5 (33%)5 (45%)0
 BMI (kg/m2)27.6 (19.8–36.6)28.0 (24.1–36.6)26.5 (19.8–31.8)
 Systolic BP (mmHg)145 (112–173)155 (126–173)134 (112–149)
 Heart rate (bpm)71 (46–97)73 (46–97)69 (66–71)
 MELD score10 (6–14)11 (8–14)7.5 (6–11)
 Total bilirubin (μmol/L)24 (6–44)28 (7–44)12 (6–17)
 INR1.2 (1.0–1.6)1.3 (1.1–1.6)1.2 (1–1.5)
 Albumin (g/dL)34 (23–40)34 (23–39)36 (30–40)
 Platelet count (× 109/L)71 (26–331)71 (26–182)104 (55–331)
 AST (U/L)43 (22–122)46 (25–122)28 (22–32)
 ALT (U/L)37 (10–123)37 (12–123)26 (10–39)
Ongoing alcohol use
 Yes4 (27%)3 (27%)1 (25%)
  1. Data presented as median (range) or n (%)
  2. ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, BP blood pressure, bpm beats per minute, HBV hepatitis B virus, HCV hepatitis C virus, INR international normalised ratio, MELD model for end-stage liver disease, NAFLD non-alcoholic fatty liver disease